Breusov A A, Kul'chavenia E V
Urologiia. 2014 Nov-Dec(6):24-6.
An open, prospective, comparative, randomized, placebo-controlled study on the evaluation of the efficacy and safety of combined drug prolit super in patients with chronic abacterial prostatitis without signs of inflammation (NIH 3B category), complicated by sexual dysfunction, was performed. The study included 57 men aged 28 to 50 years. Patients in group 1 (n=29) have received daily 4 capsules of prolit super for 2 months, patients in group 2 (n=28) - placebo for the same period. Excellent results were noted in 58.6% of patients in Group 1 and in 17.9% - in group 2; good results - in 20.7 and 21.4%, satisfactory results - in 20.7 and 17.9%, respectively. Weak effect and its absence were registered only in patients in group 2 - 28.6 and 14.3% of cases, respectively. Significant adverse events or complications against the background of therapy were not observed. The results of the study allows to recommend the appointment of prolit super.in routine clinical practice for patients with chronic abacterial prostatitis without signs of inflammation, complicated by sexual dysfunction.
开展了一项开放性、前瞻性、比较性、随机、安慰剂对照研究,以评估复方药物前列利超强(Prolit Super)对伴有性功能障碍的无炎症迹象的慢性非细菌性前列腺炎(美国国立卫生研究院3B类)患者的疗效和安全性。该研究纳入了57名年龄在28至50岁的男性。第1组(n = 29)的患者每天服用4粒前列利超强胶囊,持续2个月,第2组(n = 28)的患者在同一时期服用安慰剂。第1组58.6%的患者和第2组17.9%的患者取得了优异的效果;良好效果的患者分别为20.7%和21.4%,满意效果的患者分别为20.7%和17.9%。仅在第2组患者中出现了弱效和无效情况,分别占病例的28.6%和14.3%。在治疗过程中未观察到显著的不良事件或并发症。该研究结果允许推荐在常规临床实践中为伴有性功能障碍的无炎症迹象的慢性非细菌性前列腺炎患者使用前列利超强。